X
Details:
Through the agreement, Novasep will support Celladon’s plans to produce Mydicar, which is being evaluated in the mid-stage clinical trial for the treatment of heart failure.
Lead Product(s): AAV1-based Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Mydicar
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Celladon
Deal Size: $5.4 million Upfront Cash: Undisclosed
Deal Type: Agreement December 13, 2023
Arab Pharma Expo 2024
Not Confirmed
Contact SupplierDetails:
Through the agreement, Novosep will perform the process development of the XB002 ADC. which is being evaluated in the early-stage clinical trial studies for the treatment of non-small cell lung cancer and cervical cancer.
Lead Product(s): XB002,Nivolumab
Therapeutic Area: Oncology Product Name: XB002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 07, 2021
Arab Pharma Expo 2024
Not Confirmed
Contact SupplierDetails:
The agreement aims for the manufacturing of adeno-associated virus (AAV) vectors, covering the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein and aims to restore the expression of Otoferlin.
Lead Product(s): OTOF-GT
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTOF-GT
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sensorion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2020
Arab Pharma Expo 2024
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
